Quantitative Neuromuscular Monitoring and Gastric Bypass Surgery

Description

This is a single site, prospective, non-blinded, non-randomized, before/after study. This study is designed to evaluate the impact of monitoring and reversal guidelines for neuromuscular blocking drugs on the post-operative outcomes for patients undergoing laparoscopic gastric bypass surgery.

Conditions

Sugammadex

Talk to us

Study Overview

On this page

Study Details

Study overview

This is a single site, prospective, non-blinded, non-randomized, before/after study. This study is designed to evaluate the impact of monitoring and reversal guidelines for neuromuscular blocking drugs on the post-operative outcomes for patients undergoing laparoscopic gastric bypass surgery.

A Before/After Study of the Impact of Quantitative Neuromuscular Monitoring and Sugammadex Reversal Following Gastric Bypass Surgery

Quantitative Neuromuscular Monitoring and Gastric Bypass Surgery

Condition
Sugammadex
Intervention / Treatment

-

Contacts and Locations

Sacramento

UC Davis Medical Center, Sacramento, California, United States, 95817

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * age greater than 18 years
  • * scheduled for an elective laparoscopic gastric bypass procedure
  • * age less than 18 years
  • * pregnancy
  • * prisoners
  • * significant co-existing lung disease including asthma or chronic obstructive pulmonary disease (COPD) requiring regular medication
  • * patients who require supplemental oxygen pre-operatively to maintain a hemoglobin saturation (SpO2\>98%)

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of California, Davis,

Study Record Dates

2025-07